Wegovy

pharmaceutical product

Facts

4 properties
Instance of
trade name
Has active ingredient
semaglutide[4]
Manufacturer
Novo[2]
🏷️ Also known as
de Wegovy
🔖 Identifiers · 2
RxNorm CUI
2553502

Report an error or request removal Lineage (PROV-JSON)

Press Enter · cited answer in seconds

Summary

Wegovy is a trade name[1].

🛰️ Living Edge · news-derived, source-cited

high ≥ 0.90 · emerging ≥ 0.65 · low below — calibrated against hand-rated truth (single-source .44 · two-source .62 · production-typical .70), so a band is a measurement, not a promise. High is rare by design: it needs both a supported assertion and an evidence sentence. A confirmed or contradicted chip is a Wikidata cross-check; no chip means Wikidata has no value for that property — the ordinary case here, and it says nothing either way. A confirm-only note marks a property whose check can never disagree (Wikidata's border and capital data is not exhaustive), so silence there is a limit of the check, not of the claim.

Manufacturer Novo Nordisk high0.9952 independent sources

evidence “Novo Nordisk received FDA approval for its weight-loss drug Wegovy in 2024 to lower heart risks in overweight or obese adults without diabetes.” tidende.dk · 2026-10-02 · read source

Manufacturer Novo emerging0.889 independent sources

evidence “The study was funded by Novo Nordisk, the maker of the semaglutide drugs Ozempic and Wegovy, and several of the study’s researchers reported compensation from Novo.” everydayhealth.com · read source

Show 2 low-confidence claims

Published, not hidden — scoring low is not a reason to withhold a sourced claim. A contradicted chip means Wikidata holds a different value; both are shown so you can judge.

Price $50 a month low0.612 independent sources

evidence “One pilot that researchers and providers are looking at is the new federal Medicare GLP-1 Bridge Program, a temporary project that seeks to bring down the cost of Zepbound, Wegovy and Foundayo to about $50 a month.” pleasantonweekly.com · read source

Price $50 low0.612 independent sources

evidence “One pilot that researchers and providers are looking at is the new federal Medicare GLP-1 Bridge Program, a temporary project that seeks to bring down the cost of Zepbound, Wegovy and Foundayo to about $50 a month.” pleasantonweekly.com · read source

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . bhf.org.uk. bhf.org.uk. Provenance: wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Wegovy. Retrieved November 17, 2026, from https://4ort.xyz/entity/wegovy
MLA “Wegovy.” 4ort.xyz Knowledge Graph, 4ort.xyz, 17 Nov. 2026, https://4ort.xyz/entity/wegovy.
BibTeX @misc{4ortxyz_wegovy_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Wegovy}}, year = {2026}, url = {https://4ort.xyz/entity/wegovy}, note = {Accessed: 2026-11-17}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Wegovy — https://4ort.xyz/entity/wegovy (retrieved 2026-11-17)

Canonical URL: https://4ort.xyz/entity/wegovy · Last refreshed: